The Institute is based in the science quarter at the heart of the university campus and is part of the School of Medical Sciences, Faculty of Life Sciences.
Our research encompasses the development of new cancer medicines from concept to clinic. The emphasis of our work is on drug target and biomarker interrogation in clinical samples and development of relevant in vitro and in vivo models for lead compound selection and progression. Research covers the three broad stages of cancer medicine and biomarker development: discovery, pre-clinical evaluation and clinical application.
We are also the GcLP PKPD laboratory support for the Leeds-Bradford Experimental Cancer Medicines Centre.
- We are one of a few centres nationally that has all the necessary research tools and expertise in-house to progress anticancer medicines and biomarkers from concept to the clinic
- In the REF2014 assessment of Allied Health research placed 92% of it in the 4* and 3* categories, and 100% of the impact and environment in 4* and 3*
- Our research programmes include Phase I clinical trials support through its partnership with the Experimental Cancer Medicines Centre, St James’s University Hospital, Leeds and other clinicians based in Leeds and Bradford hospitals